Phanes Biotech Inc
12:15 PM - 12:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Presentation Description: Phanes Biotech is a biotech company developing novel therapies for the treatment of neurodegenerative diseases.
Our platforms – 1) Immunotherapy Platform - PB43D and others - is a highly potent antibody towards tau, only antibody to have proven to reduce both tau and Aβ pathologies in early animal studies. PB43D is a unique, highly potent tau monoclonal antibody (mAb) twhich can clear not only tau but also Aβ pathology and rescue cognitive impairment in the 3xTg- mouse model of AD and tauopathy.
(2) Neuroregeneration Platform - P021, a peptide molecule proven to prevent the destruction of nerve cells and to regenerate destroyed nerve cells. P021 thus functions as a disease-modifying drug that can provide never before demonstrated clinical benefits in patients with Alzheimer’s disease, macular degeneration, and other neurodegenerative diseases and of their caregivers.
We are looking for potential partners and strategic investors for both our drug development platforms.
Who referred you to this application?: NIH
Our platforms – 1) Immunotherapy Platform - PB43D and others - is a highly potent antibody towards tau, only antibody to have proven to reduce both tau and Aβ pathologies in early animal studies. PB43D is a unique, highly potent tau monoclonal antibody (mAb) twhich can clear not only tau but also Aβ pathology and rescue cognitive impairment in the 3xTg- mouse model of AD and tauopathy.
(2) Neuroregeneration Platform - P021, a peptide molecule proven to prevent the destruction of nerve cells and to regenerate destroyed nerve cells. P021 thus functions as a disease-modifying drug that can provide never before demonstrated clinical benefits in patients with Alzheimer’s disease, macular degeneration, and other neurodegenerative diseases and of their caregivers.
We are looking for potential partners and strategic investors for both our drug development platforms.
Who referred you to this application?: NIH
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
2020
Development Phase of Primary Product:
Pre Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2 products - Immunotherapy Platform - PB43D and Neuroregenerative
Speaker
